How should heavy menstrual bleeding with large clots caused by pelvic congestion syndrome be managed?

Management of Heavy Menstrual Bleeding with Large Clots from Pelvic Congestion Syndrome

For heavy menstrual bleeding with large clots caused by pelvic congestion syndrome, initiate tranexamic acid (TXA) 1-1.3g three times daily during menses as first-line medical therapy, combined with hormonal suppression using either a levonorgestrel-releasing intrauterine system (LNG-IUS) or combined hormonal contraceptives, while simultaneously referring to interventional radiology for consideration of ovarian vein embolization, which provides definitive treatment with 70-90% long-term symptomatic relief. 1, 2

Initial Medical Management

First-Line Pharmacotherapy

• Start tranexamic acid (TXA) during menstruation at 1-1.3g three times daily for 5-7 days per cycle, as it is the preferred hemostatic agent for heavy menstrual bleeding and can be used alone or combined with hormonal treatments 3, 4, 2

• Add hormonal suppression immediately, choosing between:

  • LNG-IUS (Mirena) as the most effective hormonal option for reducing menstrual blood loss 2
  • Combined oral contraceptive pills (COCPs) as an alternative, particularly if contraception is desired 3, 2

• NSAIDs (ibuprofen or mefenamic acid) for 5-7 days during menses can reduce bleeding by 20-50% and provide pain relief from pelvic congestion 4

Important Caveat on Combined Therapy

When using TXA with COCPs, the majority of clinicians (53%) add TXA to existing COCP therapy rather than using either alone 3. This combination addresses both the hormonal and hemostatic components of bleeding.

Definitive Treatment: Ovarian Vein Embolization

When to Refer for Embolization

• Refer to interventional radiology early in the treatment course, as transcatheter ovarian vein embolization (OVE) has superseded conservative and surgical management with technical success rates of 96-100% 1

• OVE provides complete or partial symptom improvement in 68.2-100% of patients with long-term relief in 70-90% of cases 1, 5

• Embolization is the least invasive and most efficacious management option compared to pharmacologic ovarian suppression, hysterectomy, or ovarian vein resection 5

Diagnostic Confirmation Before Embolization

• Non-invasive imaging (ultrasound, CT, or MRI) is essential to confirm pelvic venous congestion and exclude other causes of chronic pelvic pain 1, 6

• Transcatheter venography remains the gold standard for definitive diagnosis and is performed immediately before embolization 1, 6

Mandatory Laboratory Evaluation

Before initiating any treatment, obtain:

• Pregnancy test (beta-hCG) in all reproductive-age individuals to rule out pregnancy-related hemorrhage 7

• Complete blood count (CBC) to detect anemia from blood loss and evaluate platelet abnormalities 7

• Von Willebrand disease (VWD) screening panel including VWF antigen, VWF ristocetin cofactor activity, and Factor VIII, as VWD affects up to 1% of the population and causes heavy menstrual bleeding in 90% of affected women 7, 2

• Prothrombin time (PT) and activated partial thromboplastin time (PTT) to screen for coagulation factor deficiencies 7

• Thyroid-stimulating hormone (TSH) because thyroid dysfunction can cause anovulatory bleeding 7

Treatment Algorithm for Refractory Cases

If First-Line Medical Therapy Fails

• Discontinue COCP and insert LNG-IUS if not already in place (19% of clinicians choose this as second-line) 3

• Add DDAVP (desmopressin) to existing hormonal therapy if bleeding disorder is suspected or confirmed 3, 2

• Proceed with ovarian vein embolization if medical management provides inadequate relief after 3-6 months 1, 5

If Embolization Fails (6-31.8% of patients)

• Consider endometrial ablation as a minor surgical procedure with low operative morbidity that can be performed as an outpatient 2

• Hysterectomy remains the definitive treatment when medical therapies and embolization have failed and endometrial ablation is not suitable 2

Critical Pitfalls to Avoid

• Do not delay hematologic evaluation: Up to 20% of women with heavy menstrual bleeding have an underlying inherited bleeding disorder that requires specific hemostatic therapy 2

• Do not use bleeding time or PFA-100 for VWD screening, as these lack adequate sensitivity and specificity 7

• Do not rely solely on hormonal therapy for pelvic congestion syndrome: While hormonal treatments reduce bleeding, they do not address the underlying venous pathology, which requires embolization for definitive treatment 1, 5

• Recognize that 6-31.8% of patients do not achieve substantial relief from embolization alone, requiring additional interventions 5

• Be aware that pelvic congestion syndrome is often underdiagnosed: Patients may present to multiple specialists (gynecologists, pain specialists, gastroenterologists) before correct diagnosis, leading to anxiety and depression 1

Special Considerations

• Pelvic congestion syndrome typically affects multiparous women and is characterized by chronic pelvic pain worsened pre-menstrually, with standing, walking, and fatigue 1, 8

• Associated symptoms include post-coital ache, dysmenorrhea, dyspareunia, bladder irritability, and rectal discomfort, which help distinguish this from other causes of heavy menstrual bleeding 1

• A multidisciplinary approach involving gynecology, interventional radiology, and hematology is vital for optimal diagnosis and management 1